TransMedics (TMDX)

Executive Summary

TransMedics is a commercial-stage medical device company pioneering the Organ Care System (OCS), the first FDA-approved ex-vivo normothermic perfusion technology for preserving and transporting lungs, hearts, and livers. By maintaining organs in a warm, beating state, OCS significantly extends preservation time and improves organ quality, leading to higher utilization rates and better transplant outcomes. The company has established a strong foothold in the U.S. transplant market, with adoption growing at major transplant centers. With a total addressable market exceeding $3 billion and underutilization of donor organs globally, TransMedics is poised for sustained growth as it expands both its product indications and geographic reach. Financially, TransMedics has demonstrated robust revenue growth, driven by increasing OCS case volumes and recurring consumable sales. The company achieved profitability in 2025 and continues to invest in clinical evidence and commercial infrastructure. Key upcoming catalysts include potential FDA approval for pediatric transplantation, expansion into European markets via CE Marking, and the launch of next-generation OCS devices with enhanced monitoring capabilities. With a differentiated technology and strong clinical data, TransMedics is well-positioned to capture significant market share and drive long-term value.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for Pediatric Heart Transplantation70% success
• Q4 2026CE Mark for OCS Liver in Europe65% success
• Q1 2027Launch of Next-Generation OCS Platform80% success